#washingtonexaminer #novonordisk #elililly #ozempic #weightloss #diabetes #publichealth
Stock prices for the pharmaceutical giant Novo Nordisk have fallen dramatically following a new finding that the active ingredient in its obesity management drug, semaglutide, is less effective than Eli Lilly’s competitor product.
A first-of-its-kind study was published Monday in JAMA Internal Medicine comparing semaglutide, the active ingredient in Novo’s Ozempic and Wegovy, to tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound. Researchers found that patients on tirzepatide lost substantially more weight than those on semaglutide, sending ripples through the market.
Read the full story here:
www.washingtonexaminer.com/po...
Check out our website:
www.washingtonexaminer.com/
Негізгі бет Novo Nordisk stock price falls after Eli Lilly weight loss drug outperforms Ozempic
Пікірлер